Endpoints News· @endpts · X·· 2 小时前精选AI 评分82
AI 导读
礼来retatrutide在3期试验的全患者分析中，使60%的肥胖合并2型糖尿病患者降至肥胖阈值以下。该数据来自Endpoints News对EASD26相关结果的报道。
推荐理由
礼来retatrutide三期试验全患者分析显示60%肥胖合并2型糖尿病患者降至肥胖阈值以下，可据此观察三重激动剂的减重幅度。
正文
Lilly's retatrutide brought 60% of patients with obesity and type 2 diabetes below the obesity line in an all-patient analysis of its Phase 3 trial. https://endpoints.news/easd26-lillys-triple-g-allows-60-of-patients-to-drop-below-obesity-threshold/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=
来源：Endpoints News · x.com